Chronic hepatitis C virus infection (HCV) is a major comorbidity in patients with haemophilia. Peginterferon alpha and ribavirin current standard anti-HCV therapy but there little information about safety efficacy of peginterferon alpha-2a combination these patients.In an open-label single-treatment arm cohort study, 367 haemophilia seronegative for B human immunodeficiency markers chronically infected HCV (HCV RNA>50 IU/ml at least 6 months) received 180 microg Pegasys 800-1200 mg according...

In 2009, 3 genome-wide association studies implicated IL28B single-nucleotide polymorphisms (SNPs) as the strongest genetic pretreatment predictor of sustained virological response (SVR) in hepatitis C infection. Recently, American Association for Study Liver Diseases (AASLD) and European (EASL) included testing their guidelines.The main aim this study was to develop validate a simple, rapid, inexpensive polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method...

Hepatitis C virus (HCV) infection is the most common transfusion-transmitted disease in multiply transfused patients worldwide. In this study, aim was to investigate distribution of HCV genotypes Iranian with thalassemia.Blood samples were received from 280 thalassemia chronic hepatitis who referred us start pegylated interferon-alpha plus ribavirin for duration 48 weeks. RNA viral load detected using Amplicor test (Version 2, Roche Molecular Systems). Genotyping performed by...

IL28B polymorphism is recognized as one of the most prominent predictors hepatitis C spontaneous and treatment-induced clearance. Interestingly, favorable genotypes are found to be more frequent in Asian ethnicity than Caucasian African populations, respectively. A few studies reported that there a mysterious association between virus (HCV) genotype patients with chronic but they did not give any reason for this phenomenon.The foremost purpose study was compare distribution Iranian healthy...

Despite significant advances in the treatment of chronic hepatitis C past decades, factors which can affect response rates to combination therapy; peginterferon and ribavirin, are still under study reaching sustained virological (SVR) is affected by several different factors.To investigate predictor contributing SVR Iranian patients.The present non-randomized, clinical trial was conducted on 100 patients referred Tehran Hepatitis Center 2009-2011. The were administered combined...

Treatment guidelines contraindicate ribavirin for treatment of hepatitis C virus (HCV) infection in thalassemia major patients. Nevertheless, the current evidence suggests that might be tolerated by these patients.Despite this evidence, low dose combination therapy has not been compared with peginterferon monotherapy patients so far.Two hundred eighty detectable HCV-RNA PCR (≥ 50 IU/mL) and liver histology consistent chronic HCV were self-assigned to receive alfa-2a (n = 81) or its...

About 30% of individuals with hepatitis C virus (HCV) infection are able to clear HCV spontaneously. Differences in host genetics affect the outcome infection. Single nucleotide polymorphisms (SNPs) Interferon lambda (IFNL) genes were associated spontaneous and treatment-induced clearance infection.The aim this study was evaluate association between IFNL4 rs12979860 SNP Iranian population.A case-control designed on 91 cases 259 patients persistent as control group. The assessed most common...

Background and aim. The combination of Sofosbuvir (SOF) Ledipasvir (LDV) has been lead to considerable enhancement treatment hepatitis C virus (HCV) genotype 1 infection. A meta-analysis the currently available studies was undertaken with aim evaluate antiviral efficacy SOF/LDV therapy for 12 or 24 weeks without Ribavirin (RBV) in patients HCV Material methods. In this meta-analysis, we searched databases including PubMed, Scopus, Science Direct Web using appropriate keywords. All papers...

Background: Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. In these patients, iron overload and their comorbidities make difficulties during Pegylated-Interferon (PEG-IFN) Ribavirin (RBV) therapy. Objectives: We aimed to assess impact polymorphisms near IL28B gene on virological response HCV - infected who were treated with PEG-IFN RBV. Patients Methods: This cross sectional study was conducted 143 patients chronic hepatitis C, a combination RBV regimen....

Background: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed assess impact of IFNL4 polymorphism on response pegylated-IFN alpha (Peg-IFN-α) and ribavirin (RBV) hemophilic patients chronic (CHC). Materials Methods: In this retrospective study, 92 CHC who were treated Peg-IFN-α/RBV investigated. Single-nucleotide polymorphisms (SNPs) IFNL genomic region including...

Background:The aim of this study was to determine whether two polymorphisms the human interferon lambda 4 (IFNL4) gene (rs12979860 and rs8099917) can predict sustained virologic response (SVR) following antiviral therapy in patients with inherited bleeding disorder chronic hepatitis C (CHC).Methods: This retrospective conducted on 294 congenital CHC who were treated Peg-Interferon-α (PegIFN) Ribavirin (RBV).Baseline patient viral parameters measured analyzed statistically assess their...

Background: Hepatitis C virus (HCV), as a global health concern, has infected around 1.6% of the world population. Introduction direct-acting antiviral regimens such sofosbuvir/ledipasvir (SOF/LDV) made treatment HCV infection superior to previous therapies in terms efficacy and feasibility. The current study aimed at assessing safety generic SOF/LDV Iranian patients with infection. Methods: prospective, cohort was conducted on referred Middle East Liver Diseases Center 2016. Patients...

Most thalassemic patients with chronic hepatitis C virus (HCV) infection do not respond to therapy pegylated interferon (Peg-IFN) plus ribavirin (RBV) due hepatic siderosis and RBV dose reduction caused by RBV-induced anemia.In the present study, we recruited HCV genotype 1-infected who had relapsed after a 48-week treatment Peg-IFN in order evaluate efficacy of 72-week regimen RBV.In this retrospective 23 1 prior relapse for 48 weeks were consecutively enrolled study evaluation regimen.For...

SUMMARY Background Hepatitis B is a significant health problem and more than 350 million individuals are infected with hepatitis virus ( HBV ) globally. About 5% of these coinfected D HDV ). HBV–HDV coinfection increases the rate fulminant hepatitis, chronic cirrhosis. This study aimed to evaluate epidemiology in positive for surface antigen HBsAg who were referred Tehran Blood Transfusion Clinic from 2011 2012. Materials Methods ‐positive attending this clinic tested anti‐HDAg antibodies...

Abstract Blood-borne viruses including Hepatitis B and C, HIV, HTLV-1 parvovirus B19 are still a factor of concern, especially for hemophilia patients. Although the safety blood supply continues to improve worldwide, system in Afghanistan was damaged by many years conflict political instability. To date, there few studies focused on prevalence blood-borne This study is first investigate five patients four cities Kabul, Herat, Mazar-i-Sharif Jalal Abad. A total 80 male were screening presence...

Tenofovir disoproxil fumarate (TDF) is a new effective treatment option for patients with chronic hepatitis B (CHB).To evaluate TDF efficacy in nucleos(t)ide analogues (NAs)-naive Iranian CHB.The NA-naive received at least six months. The primary endpoint was the proportion of achieving complete virological response (CVR) during treatment. Multivariate Cox regression analysis determined predictive factors independently associated time to CVR. secondary endpoints were biochemical and...